Key references: Initial pharmacotherapy for social anxiety disorder in children

  • Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(5):403–39. https://www.ncbi.nlm.nih.gov/pubmed/24713617
  • Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015;30(4):183–92. https://www.ncbi.nlm.nih.gov/pubmed/25932596
  • Jane Garland E, Kutcher S, Virani A, Elbe D. Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice. J Can Acad Child Adolesc Psychiatry 2016;25(1):4–10. https://www.ncbi.nlm.nih.gov/pubmed/27047551
  • Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14 Suppl 1:S1. https://www.ncbi.nlm.nih.gov/pubmed/25081580
  • Korczak D, Canadian Paediatric Society Mental Health and Developmental Disabilities Committee . Use of selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness. Paediatrics & Child Health 2013;18(9):487–91. https://academic.oup.com/pch/article/18/9/487/4636236
  • Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320. https://www.ncbi.nlm.nih.gov/pubmed/26376805